A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2006
10/25/2006	CN1852730A Modulators of P-selectin glycoprotein ligand 1
10/25/2006	CN1852721A Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers
10/25/2006	CN1852720A Pharmaceutical composition and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen agonist/antagonist
10/25/2006	CN1852703A Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
10/25/2006	CN1850274A Nano complex eye drops containing liposoluble compound drug and its preparing method
10/25/2006	CN1850272A Medicine for treating alopecia areata and its clinical use
10/25/2006	CN1850271A Method for treating neurasthenia or somatic form disorders and medicinal composition
10/25/2006	CN1850061A Use of triethylene-tetramine as antitumour auxiliary drug
10/25/2006	CN1850057A Method for preparing insoluble drug single-tablet-core single-chamber osmotic pump sustained-release preparations and its product
10/25/2006	CN1850052A Loaded vascular inhibitor and cellulutoxic drug slow-release injection
10/25/2006	CN1850051A Loaded vascular inhibitor and cellulotoxic drug anticancer slow-release injection
10/25/2006	CN1850050A Compound anticancer slow-release injection containing vascular inhibitor
10/25/2006	CN1850049A Loaded vascular inhibitor and cellulotoxic drug anticancer slow-release injection
10/25/2006	CN1850048A Anticancer slow-release injection containing vascular inhibitor
10/25/2006	CN1850047A Slow-release preparation containing beta-lactamase inhibitor and cephalosporin and its use
10/25/2006	CN1850046A Slow-release preparation containing beta-lactamase inhibitor and its use
10/25/2006	CN1850045A Slow-release preparation containing macrolides anti biotics
10/25/2006	CN1850044A Slow-release injecta containing amino glucosides antibiotics and use thereof
10/25/2006	CN1850043A Slow-release injecta containing platinums compound and its synergist
10/25/2006	CN1850042A Anti-cancer slow-release preparation containing platinum medicines and its synergist
10/25/2006	CN1850041A Anticancer medicine slow-release preparation containing platinum compound and its synergist
10/25/2006	CN1850040A Loaded platinum drug and its synergist anticancer drug slow release agent
10/25/2006	CN1850039A Compound platinum medicine slow-release preparation
10/25/2006	CN1850038A Slow-release injecta containing blood vessel inhibitor and synergist thereof
10/25/2006	CN1850037A Compound anti-cancer slow-release injected containing blood vessel inhibitor
10/25/2006	CN1850033A Water soluble anti-cancer medicine slow-release fiber preparation and preparing method therefor
10/25/2006	CN1281608C New azo-indolyl derivatives
10/25/2006	CN1281274C 6-fluorobicyclo [3.1.0] hexane derivatives
10/25/2006	CN1281210C Application of Schisandrin-B in preparing medicine for treating tumor
10/24/2006	US7125979 Upstream control elements of the proopiomelanocortin gene and their use
10/24/2006	US7125970 Host cells; drug screening; antigrowth agents
10/24/2006	US7125892 Aryl aniline β2 adrenergic receptor agonists
10/24/2006	US7125889 Administering mixtures of heterocyclic imines and anticoagulants such as heparin or aspirin, to reduce blood coagualtion in mammals
10/24/2006	US7125886 2-imidazomethyl- pyrido(4,3-b)indol-1-one or -carbazol-1-one derivatives containing an ester group; especially for treating irritable bowel syndrome.
10/24/2006	US7125883 alpha v beta 3 integrin receptor modulators; treating variety of diseases including cardiovascular disorders, retinopathy, strokes, cancer, osteoporosis, tumor metastasis, high blood pressure, psoriasis, antiviral, antimycotic, antiparasitic or antibacterial therapy; 1,2-dihydropyrimidin-2-one moiety
10/24/2006	US7125882 Applying dimethylaminoethanol, tyrosine, and sulfur compound such as lipoic acid, glutathione, sulfur, resorcinol, resorcinol monoacetate, and/or sulfacetamide; skin sensitivity; side effect reduction
10/24/2006	US7125879 Prevention reproduction of virus
10/24/2006	US7125873 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
10/24/2006	US7125866 Therapeutic applications of pro-apoptotic benzodiazepines
10/24/2006	US7125864 Benzothiazepine derivatives for the treatment of hyperlipidemia
10/24/2006	US7125860 Cross-linked derivatives of hyaluronic acid
10/24/2006	US7125858 Hyaluronic acid in the treatment of cancer
10/24/2006	US7125855 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
10/24/2006	US7125848 Administering conotoxins
10/24/2006	US7125842 Anti-fungal compounds and methods of use
10/24/2006	US7125708 Composition comprising a Lactobacillus pentosus strain and uses thereof
10/24/2006	US7125699 for treating solid tumours, macular degeneration, corneal rejection, psoriasis, rheumatoid arthritis and chronic ulceration, and diseases involving vascular insufficiency, including stroke and following heart attack
10/24/2006	US7125687 Presenilin enhancers assays
10/24/2006	US7125684 Treating fertility disorders; maternal-antigen-that-embryos-require (MATER)
10/24/2006	US7125678 Protein biopolymer markers predictive of type II diabetes
10/24/2006	US7125559 Cosmetic or dermatological composition comprising a combination of an elastase inhibitor of the N-acylaminoamide family and at least one myorelaxing agent
10/24/2006	US7125542 Methods and compositions for treating conditions of the eye
10/24/2006	CA2261848C Cell adhesion inhibitors
10/24/2006	CA2253811C Taste masked liquid suspensions
10/24/2006	CA2222517C Agents for use against parasitic protozoa
10/24/2006	CA2208199C Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
10/19/2006	WO2006109855A1 Peptide having food intake stimulating effect and method for screening for the peptide
10/19/2006	WO2006109635A1 Intestinal absorptive anti-tumor agent
10/19/2006	WO2006109193A2 Selection of highly efficient antigen presenting cells for regulating immunity and uses thereof
10/19/2006	WO2006109092A1 Conjugate comprising p21 protein for the treatment of cancer
10/19/2006	WO2006108670A2 Use of cd25 antibodies in immunotherapy
10/19/2006	WO2006108667A2 Method of treatment using gh antagonist and somatostatin agonist
10/19/2006	WO2006108262A2 Regulation of neurotrophins
10/19/2006	WO2006108239A1 Ocular drug delivery
10/19/2006	WO2006087577A3 Inhibition or treatment of dyskinesia
10/19/2006	WO2006077407A3 Modulators of itch ubiquitinase activity
10/19/2006	WO2006076240A3 Compositions, products and methods for controlling weight in a mammal
10/19/2006	WO2006074094A3 Method for producing probiotically derived compounds
10/19/2006	WO2006029893A3 Composition for inhibiting or preventing the formation of a biofilm
10/19/2006	WO2005104790A3 Treatment of muscular dystrophy with mobilized peripheral blood pluripotent cells
10/19/2006	WO2005070072A3 Reciprocal regulation of inflammation and lipid metabolism by liver x receptors
10/19/2006	WO2003027637A3 Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior
10/19/2006	US20060235503 Local drug delivery devices and methods for maintaining the drug coatings thereon
10/19/2006	US20060235272 Thermopolymer composition and related methods
10/19/2006	US20060235265 Cardiac support device with anti-fibrosis coating
10/19/2006	US20060235085 determining removability performance of the virus removal membrane; storage stability and pH stability, being useful as viral substitute particles for use in an integrity test for virus removal membrane
10/19/2006	US20060235059 administering two or more timed doses of 7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methylsulfanyl-thiazol-4-yl)-vinyl]-4,17-dioxa-bicyclo[14.1.0]heptadecane-5,9-dione also called epothilone b; treating a drug resistant tumor
10/19/2006	US20060235049 1-{3-[4-(1-Methyl-pyrrolidin-2-yl)-phenoxy]-propyl}-piperidine, and 1-Benzyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperidin-4-ol; histamin receptor antagonist; antidepressant; upper airway allergies, nasal congestion, allergic rhinitis, cognitive dysfunction, schizophrenia, manic disorders
10/19/2006	US20060235023 Inhibitors of macrophage migration inhibitory factor and methods for indentifying the same
10/19/2006	US20060234991 Combinations for the treatment of immunoinflammatory disorders
10/19/2006	US20060234985 Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor
10/19/2006	US20060234982 Compositions and methods for combination antiviral therapy
10/19/2006	US20060234949 Adduct of topiramate and tramadol hydrochloride and uses thereof
10/19/2006	US20060234946 Use of telmisartan for the prevention and treatment of vascular headache
10/19/2006	US20060234937 Modulation of angiogenesis
10/19/2006	US20060234932 Prolonged efficacy of islet neogenesis therapy methods with a gastrin/CCK receptor ligand and an EGF receptor ligand composition in subjects with preexisting diabetes
10/19/2006	US20060234927 Neuroprotective iron chelators and pharmaceutical compositions comprising them
10/19/2006	US20060234924 A kit for screening a compound or its salt that promotes or inhibits the activity of the proteins; drug screening for hyperlipemia, arteriosclerosis, genital, digestive, respiratory diseases, renal, pancreatic, central nerve, respiratory, inflammatory, rheumatoid diseases and diabetic neurosis
10/19/2006	US20060234344 Protein kinases
10/19/2006	US20060234342 Human DNA topoisomerase I alpha
10/19/2006	US20060234294 Functional domain and associated molecule of dock2 essentially required in lymphocyte migration
10/19/2006	US20060233899 Treatment of Human Multiple Myeloma by Curcumin
10/19/2006	US20060233890 Method for treating a mammal by administration of a compound having the ability to release CO
10/19/2006	US20060233885 Analgesic agent for newborn or fetal subjects
10/19/2006	US20060233880 Controlled release dosage forms
10/19/2006	US20060233879 Reduced contact of the active ingredient in solid form with the mucosa lining the gastrointestinal tract, advantageous for delivering an ulcerative drug
10/19/2006	US20060233841 Implantable gel compositions and method of manufacture
10/19/2006	US20060233818 Organic compounds
10/19/2006	US20060233811 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
10/19/2006	US20060233807 Novel therapies and methods of screening for therapeutic compounds

1 ... 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 ... 1151